Michael Gelband’s Ultragenyx Pharmaceutical RARE Stock Holding History

Michael Gelband’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,392	Closed	-$3.16M	–	2003
2025 Q4	$3.16M	Buy	137,392 +30,817	+29%	+$1.01M	0.02%	621
2025 Q3	$3.21M	Buy	+106,575	New	+$3.2M	0.03%	564
2025 Q2	–	Sell	-7,991	Closed	-$289K	–	1896
2025 Q1	$289K	Sell	7,991 -79,026	-91%	-$3.29M	﹤0.01%	1235
2024 Q4	$3.66M	Buy	+87,017	New	+$4.32M	0.03%	531
2024 Q2	–	Sell	-38,025	Closed	-$1.77M	–	1901
2024 Q1	$1.77M	Buy	+38,025	New	+$1.79M	0.01%	754
2023 Q2	–	Sell	-70,864	Closed	-$2.84M	–	2179
2023 Q1	$2.84M	Buy	+70,864	New	+$3.04M	0.02%	741
2022 Q4	–	Sell	-27,980	Closed	-$1.16M	–	2042
2022 Q3	$1.16M	Buy	+27,980	New	+$1.44M	0.02%	1049
2021 Q3	–	Sell	-31,991	Closed	-$3.05M	–	2536
2021 Q2	$3.05M	Buy	+31,991	New	+$3.33M	0.03%	510
2020 Q4	–	Sell	-2,965	Closed	-$244K	–	2309
2020 Q3	$244K	Buy	+2,965	New	+$246K	﹤0.01%	1387

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Michael Gelband's RARE Position: Q1 2026 in Review

Michael Gelband sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 137,392 shares — an estimated $3.16M sold.

Michael Gelband first reported a position in RARE in Q3 2020 and held it in 9 quarters. The position peaked at $3.66M in Q4 2024. 297 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Michael Gelband reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 137,392 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.16M.
Michael Gelband first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 9 quarters.
Michael Gelband's Ultragenyx Pharmaceutical position peaked at $3.66M in Q4 2024.
297 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.